INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L...

Full description

Saved in:
Bibliographic Details
Main Authors KELLY, Patrick F, ASHWELL, Susan
Format Patent
LanguageEnglish
French
Published 19.11.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S. Les patients diagnostiqués avec un cancer présentant une mutation IDH-1 peuvent être traités par l'administration d'une quantité thérapeutiquement efficace d'une composition pharmaceutique comprenant le composé 1, un inhibiteur sélectif de la production de 2-HG à partir d'enzymes mIDH -1 comprenant les mutations R132 suivantes : R132C, R132H, R132L, R132G, et R132S.
Bibliography:Application Number: WO2020US33212